Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation
- 1 July 2001
- journal article
- review article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 29 (7), S90-S94
- https://doi.org/10.1097/00003246-200107001-00028
Abstract
In the pathogenesis of disseminated intravascular coagulation, dysfunctional natural anticoagulant pathways appear to play a pivotal role. In this article, we will address the mechanisms that contribute to this defect in the regulation of coagulation activation. Furthermore, we will explore the experimental and clinical evidence that restoration of these anticoagulant pathways results in clinical improvement. We have searched and reviewed published articles on experimental studies of disseminated intravascular coagulation models in animals and clinical studies in patients with disseminated intravascular coagulation. All three major anticoagulant pathways, that is, the antithrombin pathway, the protein C system, and tissue factor pathway inhibitor, are defective in sepsis and disseminated intravascular coagulation. Several mechanisms contribute to this defect. Restoration of these pathways, in principle, by administration of coagulation inhibitor concentrates or recombinant anticoagulant factors, appears to ameliorate the coagulation disorder and, more important, result in improvement of clinically relevant outcomes, such as a reduction of organ failure and mortality. Restoration of disrupted physiologic anticoagulant pathways in disseminated intravascular coagulation is not only a logical point of impact in patients with sepsis and an activated coagulation system, but also is associated with an improved outcome in experimental and (initial) clinical studies.Keywords
This publication has 42 references indexed in Scilit:
- The protein C pathwayCritical Care Medicine, 2000
- Novel approaches to the management of disseminated intravascular coagulationCritical Care Medicine, 2000
- Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coliBlood, 2000
- Disseminated Intravascular CoagulationNew England Journal of Medicine, 1999
- Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patientsBlood, 1996
- Coagulation disorders in septic shockIntensive Care Medicine, 1993
- Septic Shock, Multiple Organ Failure, and Disseminated Intravascular CoagulationChest, 1992
- Acquired antithrombin III deficiency: Laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrateAmerican Journal Of Medicine, 1989
- The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution*European Journal of Haematology, 1989
- Modulation of endothelial cell hemostatic properties by tumor necrosis factor.The Journal of Experimental Medicine, 1986